|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||11.11 / 28.50|
The big question right now is to what degree should you be looking to take positions in individual stocks you may like.
These names are displaying bullish and bearish reversal patters over the last week.
Investors eyeing a purchase of Cara Therapeutics Inc shares, but cautious about paying the going market price of $12.46/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2019 put at the $7.50 strike, which has a bid at the time of this writing of 95 cents.
Jim Cramer is bullish on Cara Therapeutics, Thomson Reuters, Wynn Resorts, and Edison International.
It's just very hard to keep stocks down in this environment, says Jim Cramer. It's part of a synchronized global expansion.
The most recent short interest data has been released for the 10/31/2017 settlement date, which shows a 1,149,738 share decrease in total short interest for Cara Therapeutics Inc , to 7,361,067, a decrease of 13.51% since 10/13/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Management to host conference call today at 4:30 p.m. ET
Trial to evaluate pharmacokinetics and safety of three tablet strengths of Oral CR845
Study to inform dose selection and design of Phase 2 trial in non-hemodialysis patients with chronic kidney disease-associated pruritus (CKD-aP)
Data from respiratory safety trial of I.V. CR845 to be detailed in oral presentation
The South San Francisco, Calif.-based company said Oct. 16 its Phase 3 study of cabozantinib achieved its primary endpoint of overall survival in patients that have advanced hepatocellular carcinoma.
Phase 3 pivotal program in hemodialysis patients expected to commence in Q4 2017
Investors eyeing a purchase of Cara Therapeutics Inc shares, but tentative about paying the going market price of $13.17/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the May 2018 put at the $10 strike, which has a bid at the time of this writing of $1.50.
In trading on Friday, shares of Cara Therapeutics Inc crossed above their 200 day moving average of $14.10, changing hands as high as $16.00 per share. Cara Therapeutics Inc shares are currently trading up about 14.9% on the day.
Conference call today at 4:30 p.m. ET
There still will be winners and losers, but the new administration's FDA is a net plus for the industry.
Tablet strengths exhibiting appropriate plasma levels identified for potential use in general CKD-associated pruritus patients
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.